Hikma Pharmaceuticals Plc Signing of Exclusive Agreement with Theravance (2028I)
July 01 2013 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 2028I
Hikma Pharmaceuticals Plc
01 July 2013
Hikma licenses VIBATIV(R) from Theravance
London, 1 July 2013 - Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (NASDAQ Dubai: HIK) today announces the signing of an
exclusive commercialisation agreement with Theravance, Inc.
("Theravance") (NASDAQ: THRX) for VIBATIV(R) (telavancin) in the
Middle East and North Africa ("MENA") region. VIBATIV(R) is a
bactericidal, once-daily lipoglycopeptideinjectable antibiotic for
Gram-positive bacterial infections, including methicillin-resistant
Staphylococcus aureus (MRSA).
Under the terms of the agreement, Hikma will have the exclusive
rights to register, market and distribute VIBATIV(R) in 16
countries across MENA. The agreement will leverage Hikma's strong
local presence and regulatory expertise in MENA, with over 1,600
sales and marketing reps across the region.
MRSA is currently the most dangerous skin and soft tissue
infection ("SSTI") pathogen, causing serious infections in both
hospitalised patients and patients in the community.[1] MRSA rates
are increasing rapidly in many regions and there is a dynamic
spread of strains across the globe.[2]
Said Darwazah, Hikma's CEO said, "We are pleased to be
partnering with Theravance to bring VIBATIV(R) to patients in the
MENA region. VIBATIV(R) is an excellent product that will enhance
our broad portfolio of anti-infective products and offers a good
market opportunity. Strengthening our product portfolio through
partnerships such as this continues to be a key component of our
MENA growth strategy."
--- ENDS ---
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/
07776 477050
Lucinda Henderson, Investor Relations Manager +44 (0)20 7399
2765/ 07818 060211
FTI Consulting +44 (0)20 7831 3113
Ben Atwell /Julia Phillips/Matthew Cole
About Hikma
Hikma Pharmaceuticals is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based principally in the
Middle East and North Africa (MENA) region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenue of US$1,108.7 million and profit attributable to
shareholders of US$100.3 million.
About VIBATIV(R)
VIBATIV(R) is a bactericidal, once-daily, injectable
lipoglycopeptide antibiotic with a dual mechanism of action whereby
VIBATIV(R) both inhibits bacterial cell wall synthesis and disrupts
bacterial cell membrane function. VIBATIV(R), discovered and
developed by Theravance, is approved in the United States for the
treatment of adult patients with complicated skin and skin
structure infections ("cSSSI") caused by susceptible isolates of
Gram-positive bacteria, including Staphylococcus aureus, both
methicillin-susceptible (MSSA) and methicillin-resistant (MRSA)
strains. In June 2013 VIBATIV(R) was approved by the U.S. Food and
Drug Administration for the treatment of adult patients with
hospital-acquired and ventilator-associated bacterial pneumonia
(HABP/VABP) caused by susceptible isolates of Staphylococcus aureus
when alternative treatments are not suitable.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of
internally discovered product candidates and strategic
collaborations with pharmaceutical companies. Theravance is focused
on the discovery, development and commercialisation of small
molecule medicines across a number of therapeutic areas including
respiratory disease, bacterial infections and central nervous
system (CNS)/pain. Theravance's key programmes include: RELVAR(TM)
ELLIPTA(TM) or BREO(TM) ELLIPTA(TM) (FF/VI), ANORO(TM) ELLIPTA(TM)
(UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta(2)
Agonist), each partnered with GlaxoSmithKline plc, and its oral
Peripheral Mu Opioid Receptor Antagonist program. By leveraging its
proprietary insight of multivalency to drug discovery, Theravance
is pursuing a best-in-class strategy designed to discover superior
medicines in areas of significant unmet medical need. For more
information, please visit Theravance's web site at
www.theravance.com.
THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R) are registered trademarks of Theravance, Inc.
VIBATIV(R) is a registered trademark of Theravance, Inc.
RELVAR(TM), BREO(TM), ANORO(TM) and ELLIPTA(TM) are trademarks
of the GlaxoSmithKline group of companies. The use of the brand
names ANORO(TM) and RELVAR(TM) has not yet been approved by any
regulatory authority.
[1] Datamonitor, Skin and skin structure infections, 5 July
2011
[2] The 9(th) Arab Conference for Antimicrobial Agents Program
and Abstract Book, November 2012
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRBLGDLSGDBGXI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024